

Registration and authorisation form as well as authorisation and instruction form

Virtual ordinary Annual General Meeting of BioNTech SE on 17 May 2024



Last name, First name or company*

Street*

Shareholder number*

ZIP/City*

Number of shares*

* Mandatory fields

Please use one of the registration options below and send the form to the registration address by the registration deadline **on 10 May 2024, 24:00 (CEST)** to BioNTech SE, c/o Computershare Operations Center, 80249 Munich, Germany, Email: anmeldestelle@computershare.de. After registration has been completed, it is still possible to issue a power of attorney and, if necessary, instructions using this form (by mail or e-mail to the above address no later than **Thursday, 16 May 2024, 24:00 (CEST)** (time of receipt)). Since the form is processed automatically, additional information outside the specified fields cannot be taken into account.

1 Registration

My/our shareholding is hereby registered for the above-mentioned general meeting in one of the following ways.



Power of attorney and instructions to the proxies nominated by the company

I/We authorize the proxies appointed by the company (Dr. Oliver Hennig, Munich und Dirk Schreiber, Mainz) individually subject to the disclosure of my/our name(s) and with the right to sub-authorize, to represent me/us at the Virtual ordinary Annual General Meeting of BioNTech SE to be held in Mainz on 17 May 2024 and to exercise the voting rights as marked overleaf under number 3.

Please turn to give instructions. ►



Registration

I/We hereby register my/our shareholding(s).

Note: Please note that you have not yet exercised any voting rights as a result of this registration. Voting rights can be exercised in the company's Investorportal until the time set by the chairman in the Virtual ordinary Annual General Meeting. The access data for the investor portal will be sent to shareholders who are entered in the share register no later than 00:00 (CEST) on 26 April 2024.



Representation by an authorised party

I/we authorize the person named under number 2 to represent me/us at the Virtual ordinary Annual General Meeting of BioNTech SE to be held in Mainz on 17 May 2024. The authorization takes place by disclosing the name(s) and includes the exercise of all shareholder rights, including the right to vote and the right to sub-authorize. Voting rights may also be exercised by an association of shareholders. I/we have expressly informed the authorized representative of the information on data protection and the transfer of personal data. A proxy card with access data to the investor portal will be sent to the authorised third party to exercise the voting right.

2

Information about the authorized person

In this section, please enter the data of the authorized person required for processing.

First name of the authorized representative or company*

Last name of the authorized representative*

Street*

Number*

Country

ZIP*

Place or registered office of the company*

* Mandatory fields

Signature(s) resp. person(s) making the declaration (legible)

Last name, First name or company*

Street*

Shareholder number*

ZIP/City*

Number of shares*

* Mandatory fields

3

Issuing instructions

Resolution proposals according to the Federal Gazette (Bundesanzeiger)	Ja	Nein	Enthaltung
2. Resolution on the Appropriation of Balance Sheet Profit for the 2023 Financial Year	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Resolution on the Approval of the Actions of the Management Board	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Resolution on the Approval of the Actions of the Supervisory Board	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Resolution on the Appointment of the Auditor of the Annual Financial Statements and the Auditor of the Consolidated Financial Statements for the 2024 Financial Year as well as the Auditor for any Audit or Review of Interim Financial Information During the Year	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Resolution on the Approval of the Compensation Report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Resolution on the approval of the adjusted Compensation System for members of the Management Board	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Resolution on the Adjustment of the Compensation System and the Compensation of the Supervisory Board members as well as the corresponding Amendment to Art. 9 para. 6 of the Articles of Association	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Resolution on cancellation of an existing authorisation, creation of a new authorisation to issue bonds with warrants and/or convertible bonds and to exclude subscription rights, together with cancellation of existing Contingent Capital WSV 2019, creation of new Contingent Capital WSV 2024 and corresponding amendment to the Articles of Association	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Resolution on the Authorization to acquire Treasury Shares, also excluding Tender Rights, and to use them, also excluding Subscription Rights, as well as the Cancellation of the existing Authorization	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11. Resolution on the Authorization to use Derivatives in connection with the Acquisition of Treasury Shares	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12. Amendment of authorizations to issue Stock Options	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13. Resolution on the partial Cancellation of the Conditional Capital ESOP 2017/2019, the partial Cancellation and Amendment of an Authorization to issue Stock Options (ESOP 2021) as well as on the partial Cancellation of the Conditional Capital ESOP 2021, a new authorization to issue Stock Options (ESOP 2024) and the Creation of a new Conditional Capital ESOP 2024 and corresponding Amendments to the Articles of Association	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
14. Resolution on the approval of the conclusion of a Domination and Profit and Loss Transfer Agreement between BioNTech SE and BioNTech Collaborations GmbH	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

You can cast your votes on properly submitted, admissible counter motions and election proposals in the Investor Portal.